Overview

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).

Phase:

Phase 2

Details

Lead Sponsor:

Frantz Viral Therapeutics, LLC

Collaborator:

The Cleveland Clinic

Treatments:

Artemisinin
Artemisinins
Artenimol
Artesunate